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Abstract
Mild cognitive impairment (MCI), also known as incipient dementia, is characterized 
by the decline of cognitive function greater than expected for a certain age and educa-
tional level of the individual but not severe enough to interfere with their daily activi-
ties. However, this mild cognitive impairment affects several areas: visuospatial, memory, 
attention and fluency and it is a significant concern because it decreases the quality of 
life and treatment adherence of these patients. On the other hand, evidence suggests that 
individuals with Chronic obstructive pulmonary disease (COPD) also present an impor-
tant risk of falls: 46% of these patients experience a fall/year, sometimes with fatal conse-
quences. Standard clinical balance measures can predict the risk of falls in this population. 
Moreover, increased inflammatory biomarkers are associated with the decrease of cogni-
tive functions and a higher risk of falls in this population. Patients with COPD have a 
higher balance and cognitive impairment than their healthy peers Therefore, it is impor-
tant to identify, assess and understand the relevance of these comorbidities in order to 
characterize the full clinical spectrum of COPD and adjust prevention strategies, given the 
devastating consequences of these problems.
Keywords: balance, falls, dementia, cognition, COPD
1. Introduction
COPD is recognized as a disease with many systemic components [1]. Among them, the 
neuro-psychical component (anxiety/depression), has already been recognized. Besides 
this, in the last decade, research has been initiated on the neuromorphological  substrate to 
explain whether certain manifestations such as cognition alteration, the occur rence of  balance 
disorders, etc. could also be due to the impact of COPD, or would only be  manifestations 
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related to age and/or other comorbidities. This paper presents an overview of the state of 
knowledge in this last field.
1.1. Summary
• Cognition – domain and modulating factors.
• Balance disorders: nosology, prevalence, clinical consequences.
• COPD: fundamental pathophysiological mechanisms susceptible to alter cerebral function.
• Clinical consequences of affected cognition; measure methods.
• Therapeutic implications; preventive strategies.
2. Cognition: domain and modulating factors
There are multiple classifications of cognition, of which that proposed by Dal Negro seems 
the most appropriate for the purpose of this chapter. According to that, its domains and sub-
domains are: (a) executional function with the subdomains: attention, problem solving, plan-
ning and reasoning; (b) language, with the subdomains: comprehension and verbal fluency; 
(c) memory, with the subdomains: memory-based tagging and work memory; (d) praxis, with 
the subdomains: motor-ideative, ideative and visual constructive [2].
The distinction between any cognitive impairment and mild cognitive impairment (MCI) 
should be clarified. The latter refers to a brain function syndrome involving the onset and 
evolution of cognitive impairments other than those age and education related, but that are 
not significant enough to interfere with daily activities [3]. To date (2017), one of the most 
comprehensive meta-analyses that have specifically investigated prevalence MCI in the con-
text of COPD, included 23,116 people with COPD, and showed MCI prevalence of 25%, rais-
ing up to 32% if any cognitive impairment is assessed [4].
Compared to the prevalence of MCI in the general population, which is in the range of 10–20% 
in older adults, a rate of 25–32% present in patients with COPD is more than worrying [5].
But equally important is the relationship between the various cognitive domains affected in 
COPD patients and the disease itself. This is because the prevalence of impairment varies 
among the different cognitive domains. What is more, the psychometric profile impairment 
would be associated with the variable components of COPD such as hypoxemia, hypercap-
nia, lung function, exacerbations or disease severity.
Although one cannot speak about a specific profile encountered in “pure” COPD, that is, the 
one without comorbidities, the most frequently affected subdomains are attention, naming, 
visuospatial, memory, motor and executive function and mood decrements (fear and antino-
ciception) [6–10].
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We must be aware that COPD severity (hypoxemia/hypercapnia, pulmonary obstruction and 
exacerbations), factors typically present (age and smoking) as well as various combinations 
(comorbidities, education level, physical activity, nutritional status, etc.) make up in a com-
plex mosaic. Assigning cognition alterations to the underlying disease (COPD), implies for 
this reason, an extremely laborious and unlikely effort to distinguish among these factors. 
An example, in a prospective study of 62 patients with COPD, it was possible to see how 
cognitive impairment varied depending on the stage of the disease: exacerbation, at discharge 
or when the stable phase was reached; unlike other studies, this research followed the same 
patient at all 3 different stages of his disease. Cognitive assessment was measured by Montreal 
cognitive assessment (MoCA) test. From exacerbation to stable COPD, all the clinical variables 
improved step-by-step: visual-constructional, attention, language, abstraction, delayed recall 
and orientation (from exacerbation to discharge), visual-constructional and naming (from 
discharge to stable phase) and taken as a whole, from exacerbation to stable COPD: naming, 
attention, language, abstraction and delayed recall [11].
Thus, differences in studies such as (a) various study designs and methodological limita-
tions: lack of clinical assessment of airflow impairment, severity of COPD, heterogeneity of 
assessment moment (stable phase, exacerbation and long-term oxygen therapy [LTOT]), small 
sample size, lack of appropriate referent group, diagnostic criteria for cognitive impairment 
(psychometric tools and neuroimaging), (b) the use of different definition, (c) lack confounder 
adjustment procedures: comorbidities, age, active smokers, level of education, etc., may 
explain the wide range of prevalence rates of cognitive impairment in COPD from 5.5% up to 
77% [12, 13].
2.1. Balance disorders: nosology, prevalence, clinical consequences
Chronic illnesses in general as the disease progresses develop debilitating features, and 
COPD is no exception. Age and other features may include lower limb muscle weakness, 
overall fatigue, dizziness, different functional impairment, body imbalance and others [14].
Among them we will refer to balance impairment, which can lead to the loss of coordination 
and implicitly to falls.
Involuntary falls are incidents that can occur at any age, more frequently in the elderly, with 
possible devastating consequences. Individuals aged over 65 would experience at least one 
fall per year [15]. In a prospective study, the incidence of falls was more than four times higher 
in patients with COPD, than in healthy individuals with respect to gender and age [16].
Due to comorbidities, elderly patients are often polymedicated: anxiolytics/sedatives, anti-
hypertensives, corticosteroids, etc., medications that can be responsible for balance distur-
bances. According to a research conducted by Roig, the use of corticosteroid therapy in COPD 
population has been estimated to be ~61.5% for inhaled and ~8.3% for oral corticosteroids 
[17]. Corticosteroid therapy interferes with the production of contractile proteins (increase 
intracellular proteolysis) resulting in muscle weakness conducing to falls. Thus, in order to 
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relate falls to COPD we must exclude other confounders: polypharmacy, decreased vision, 
impaired mobility (arthrosis) and multiple other comorbidities.
Two other factors, such as sedentary life style and systemic inflammation, should not be neglected 
either: the former is almost constantly encountered and the latter in about 30% of cases [18].
Severe COPD stages as well as exacerbations are accompanied by an increased risk of falls [19].
Dispnoea, muscle mass loss (especially in the thighs) and decreased exercise endurance will 
reduce the ability of COPD patients to perform daily activities and limit their exercise toler-
ance, creating a downward spiral that will lead to generalized immobility [20].
Difficulties in achieving day-to-day activities and related instrumental activities contribute 
to a reduced quality of life, but in the event of falls, devastating effects may arise on global 
function and even on life expectancy. Except for a major physical trauma event, the disorder 
is resulting in loss of functional independence and social interaction.
Several studies have shown that the history of falls in the previous year is predictive of relapse [21].
Repeated falls will lead to insecurity, fear and lack of confidence in performing daily domestic 
activities. In a recent study, that included 93 patients with COPD, 32% had a degree of body 
balance impairment during the performance of dynamic activities, compared to 5% in the 
control group (p = .0005) [22].
Fear and lack of confidence in performing everyday domestic activities will develop a chronic 
status of loss of movement autonomy which can lead to muscle deconditioning, higher global 
fatigue and greater loss of body balance. As a consequence, the adherence to treatment will 
decrease, especially to rehabilitation programs [19].
The most common used tests are: the Berg Balance Scale (BBS), Falls Efficacy Scale-
International (FES-I), Timed Up and Go (TUG), single-leg stance test (SLS) and activities bal-
ance confidence (ABC).
Studies that tried to ascertain whether there is a correlation between COPD phenotypes 
and nutritional status have generated contradictory results. Some of them have found that 
the cachectic/emphysematous phenotype would be more prone to falls, considering that 
loss of skeletal muscle and weakness would be the main cause [23]. Others, by contrast, 
mention that the bronchitis/obese phenotype would have a higher risk of falls, due to 
the fact that the obese patients would record the intensity of fear more than the cachectic 
phenotype [24].
The overall conclusion is that patients with COPD have greater balance impairment than their 
healthy peers.
2.2. COPD: fundamental pathophysiological mechanisms susceptible to alter cerebral 
function
Cognitive impairment is multifactorial, but a history of cigarette smoking, aging and educa-
tional level are recognized as major determinants [25, 26]. The origin of the cerebral  dysfunction 
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in patients with COPD is still unknown, assuming the interference of several pathological 
relays: hypoxemia, oxidative stress, systemic inflammation, smoking, comorbidities, vascular-
mediated brain pathology, neurotransmitter metabolism in the central nervous system (CNS), 
a decrease in physical functioning, genetic and epigenetic factors.
Hypoxia. In 1919, Haldane had a deep insight: “partial anoxia means not an appreciable slowing 
of life, but progressive, and perhaps irreparable damage to human structure.” This “irreparable 
damage to human structure” can also include brain damage [27]. After half a century, Krop and 
colleagues observed the neuropsychological benefits of continuous oxygen therapy in COPD [28]. 
However, the first major randomized clinical trial (Nocturnal Oxygen Therapy Trials – NOTT), 
appeared in 1980, when the effects of continuous or nocturnal oxygen therapy on hypoxemic 
in COPD were investigated [29]. After the re-examination of the NOTT, it was possible to see 
that 42% of patients with COPD had moderate-to-severe cognitive impairment compared to 14% 
among controls [30]. In a follow-up of the NOTT cohort, it was observed that the neuropsycho-
logical deficit parallels the degree of hypoxia: 27% of those with mild hypoxemia to 62% in those 
with severe hypoxemia [31].
It is worthwhile discussing the mechanisms of response of the brain to hypoxemia. There is 
a very interesting mechanism for counteracting cerebral hypoxemia, the so-called cerebro-
vascular oxygen reactivity, which ensures blood flow up to 200% in the conditions of oxygen 
desaturation produced by chronic hypoxemia, nocturnal or exercise induced. For this reason, 
cerebral blood flow is much higher in hypoxemic than in non-hypoxemic COPD patients and 
even healthy controls [32, 33]. The same mechanism also explains that during rapid eye move-
ment (REM) sleep, which accounts for about 13% of total sleep time in COPD patients, there is 
no cerebral hypoxemia. Surprisingly, during nonrapid eye movement (NREM) sleep, it is not 
known why, cerebrovascular oxygen reactivity is missing [34].
Nocturnal desaturation events are commonly met in 38–70% non-hypoxemic COPD patients 
[35]. Under these conditions, when the cerebrovascular oxygen reactivity mechanism is inop-
erative, the effect of night-time desaturation should injure the central nervous system (CNS). 
This was also the goal of a study of 115 non-hypoxemic COPD patients grades 2 and 3, with-
out sleep apnoea, to which it was dosed a serum surrogate marker, namely S100B (a calcium 
binding protein produced in brain damage), and at the same time neuromuscular function via 
motor cortex activation and excitability and maximal voluntary quadriceps strength measure-
ment was assessed. Absence of cerebrovascular reactivity would be the mechanism leading to 
brain injury formation during NREM sleep desaturations, which was found in approximately 
50% of non-hypoxemic COPD patients [36].
The effort in daily activities would be likely to cause brain damage in severe COPD 
hypoxemic patients; emphasizing desaturations, inducing increase of frontal lobes choline 
(which is a reliable marker of myelin destruction with alteration of neuronal membrane 
turnover) corresponding to white matter hyperintensities on magnetic resonance imaging 
(MRI) [7].
In a study that enrolled younger patients (45–65 years) with COPD, low baseline oxygen satura-
tion (≤88%) was strongly related to cognitive impairment (adjusted OR = 5.45). But what is more 
relevant is that in the same study, regular use of supplemental oxygen therapy in home setting 
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decreased the risk for cognitive impairment (OR = 0.14; P < 0.0001) [37]. It is a recognized fact 
that long-term oxygen therapy (LTOT) is able to protect significantly (p < 0.022) the cognitive 
functions from COPD-induced deterioration. Another fact is that the patients with mild cogni-
tive impairment COPD induced are unaware of the risk that involves repetitive desaturations 
to produce conversion from mild cognitive impairment to dementia, if nothing is done with 
LTOT [38, 39].
Therefore, continuous or even intermittent hypoxia (efforts, daily activities and sleep) may 
cause changes in brain perfusion, transient deficits in neurotransmitter metabolism in the 
central nervous system with changes in brain neurochemistry and structure [7, 36, 40–42].
Although hypoxia is per se a damaging factor, it mostly acts in an additive manner in the 
development of structural abnormalities in the brain [43].
Chronic systemic inflammation. Inflammation as a driving force to the central pathology of 
the disease, in very recent years has been subjected to doubts and contestations [44]. Even in 
the definition of COPD, GOLD 2017 no longer mentions the contribution of chronic inflam-
mation to the pathophysiological process [1].
However, patients with COPD, particularly when the disease is severe and during exacerba-
tions have evidence of systemic inflammation: increased circulating cytokine, chemokine, and 
acute-phase protein levels or abnormalities in circulating cells. These mediators are derived 
from inflammatory and structural cells in the lung and interact with each other in a complex 
manner. Similar mediators that are found in the lungs of patients with COPD might also be 
increased in the circulation, presumed reached here through translocation or “spill-over”; 
this chronic low-grade systemic inflammation could underlie and potentiate comorbidities 
(muscle wasting/cachexia, cardiovascular diseases, osteoporosis, etc.) including central ner-
vous system impairment [45, 46]. The chronic inflammatory status may contribute to vessel 
wall changes (endothelial dysfunction, stiffening of arteries and arterioles and impaired vas-
cular reactivity) and may also have neurotoxic effects: synaptic dysfunction and neural cell 
apoptosis [46–49].
The inflammed endothelium overexpresses surface adhesion molecules, such as vascular cell 
adhesion molecule-1 (VCAM-1), facilitating the adherence of white blood cells to damaged 
endothelial surfaces. Interleukin 6 (IL-6) can stimulate the release of acute-phase proteins by 
hepatocytes, including C-reactive protein (CRP), serum amyloid A, fibrinogen and procoagu-
lant factors, which further promote or amplify the inflammatory process [50]. Moreover, CRP 
fosters the uptake of low-density lipoproteins (LDL) by macrophages, which contribute to the 
increased prevalence of arterial plaques containing a lipid core in patients with COPD [51]. 
Accelerated atherogenesis and impaired endothelial function, caused by a vascular inflamma-
tion status is assumed to lead to microvascular dysfunction and cerebral small vessel disease 
(microbleeds and lacunar infarcts) having as a consequence cognitive and functional impair-
ment [52].
On the other hand, COPD is frequently associated with cardiovascular diseases, obesity or 
metabolic syndrome, the contribution of comorbidities into the systemic elevation of IL-6 
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levels is difficult to disentangle. Some authors described an inflammatory-prone COPD 
 phenotype, patients with an increased risk of exacerbations (OR = 3.7) and simultaneously 
more severe cardiovascular and cerebral abnormalities [53, 54].
Acute exacerbations of COPD. These patients had significantly poorer cognitive function 
compared with control participants 3 months after discharge from hospital [55]. During a 
severe exacerbation, in the context of hypoxemia, paroxysmal inflammation (increased plate-
let activity and coagulation) and a pre-existing endothelial dysfunction, plaque rupture can 
occur and consequences will be coronary obstruction and stroke. However, other studies have 
shown that cognitive impairment during the exacerbation period recovers during periods of 
stability [56].
Smoking. Smoking has pleiotropic disastrous effects: promotes atherosclerosis (endo-
thelial changes), direct effect of neurotoxicity (heavy metal, nicotine and constituents of 
smoke), exacerbates hypoxia brain due to chronically elevated carbon monoxide causing 
a left shift of the oxyhaemoglobin dissociation curve, deteriorates lung function, favors 
the development of comorbidities which have a negative effect on cognitive processes. 
Chronic smoking is also involved in the production of pathogenic changes (decrease in 
the gray matter density) in areas where Alzheimer’s disease develops (inferior parietal 
lobule and precuneus). Moreover, its deleterious action can continue even after smoking 
cessation [57–59].
Comorbidities. It is a recognized fact that general morbidity and the burden of disease 
increases with both age and cumulative pathology, and COPD is no exception.
In a study of 52 stable non-hypoxic COPD patients, Ersel Dag et al., found that subjects with 
better functional capacity and lower comorbidity had better cognitive function; according to 
this study, the MoCA would be superior to Mini Mental Status Examination (MMSE) in detect-
ing cognitive decline [60]. A higher Charlson Comorbidity Index and a reduced functional 
level have induced cognitive decline; this is also the conclusion of another similar study with 
1 year follow-up of patients with COPD, which at baseline hospitalization lacked cognitive 
impairment [61]. Cleutjens et al. in a cross-sectional observational study on 90 stable COPD 
patients compared to 90 matched non-COPD controls, analyzed general cognitive impairment 
and domain-specific cognitive impairment using a complex battery of 6 psychometric tests, 
after correction for comorbidities using multivariate linear and logistic regression models. They 
found a prevalence rate of 56.7% for general cognitive impairment, which meant four times 
higher compared to matched non-COPD controls. The most prevalent affected domains were 
planning and cognitive flexibility, where abnormal planning was observed in 16.7% of patients 
without comorbidities but in none of the controls without comorbidities, and abnormal cogni-
tive flexibility was observed in 44.4 and 11.6% of patients and controls without comorbidities, 
respectively [9].
Diseases accompanied by hypoxemia and vascular damage (coronary heart disease, cardiac 
failure, hypertension and stroke) have a proven risk of developing neural damage that is 
amplified if active smoking is also associated [4].
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Another comorbidity present in over 20% of COPD cases is Obstructive Sleep Apnoea 
Syndrome (OSAS), a disease that underlies many common pathological pathways. 
Through recurrent hypoxia, moderate–severe forms of OSAS are able to affect cogni-
tive performance, especially by focusing on attention, complex thinking, learning and 
memory [62, 63].
Depression and anxiety are among the most common comorbidities of COPD, reaching over 
70% in oxygen-dependent cases, and much more important is that onset of depression was 
predictive of cognitive decline among COPD patients [64].
COPD was associated with baseline and incident disability which progresses over time and 
cognitive impairment was found to have an additive effect on this disability [64–66].
Therefore, cognitive comorbidities may contribute to a substantial burden of COPD-related 
morbidity, especially by impairing quality of life, reducing physical activity, reducing adher-
ence to treatment and increasing the frequency of hospital admission.
Oxidative stress. An increase in the level of reactive oxygen species (oxygen ions, free radicals 
and peroxides) leads to oxidative stress, which would alter the neuronal signals that produce 
neuro-inflammation with neuro-degeneration and implicitly with cognitive impairment [67]. 
The most important triggers for the development of oxidative stress in patients with COPD 
are cigarette smoke and systemic inflammation.
Other possible mechanisms. In a highly laborious study in 55 patients with moderate-severe 
COPD in stable period were determined: (i) cognitive ability (through a battery of 6 psycho-
metric tests), (ii) structural brain abnormalities using 3T MRI to seek signs of small vessels 
disease (white matter hyperintensities, lacunes, cerebral microbleeds and enlarged perivas-
cular spaces) and (iii) hippocampal volume as an area involved in memory process. The 55 
patients were divided into 2 subgroups, cognitively high (25 patients) and low-performing 
(30 patients), having comparable demographics, clinical characteristics and comorbidities. No 
structural changes were found between COPD patients with low or high cognitive perfor-
mance, demonstrating that small vessels disease would not represent a pathological pathway 
[68]. On the contrary, other authors provided evidence of significant white and gray matter 
abnormalities associated with cognitive dysfunction in patients with COPD without arterial 
hypoxemia or hypercapnia. Given the paucity in current evidence, more research is needed 
to evaluate the impact of cerebral small vessel disease on stroke and cognitive functioning in 
patients with COPD [69, 70].
Mitochondria are the intracellular organelles that provide aerobic respiration and cellular 
energy. As a result, mitochondrial diseases have as expression and localization the most 
oxygen-consuming tissues: skeletal muscles, central nervous system and heart. Depending 
on the load of mutant mitochondrial genomes, neurological expression ranges from mild 
cognitive impairment to dementia, or epilepsy, stroke-like episodes, ataxia, etc. In COPD, 
there are approximately 20% of cachexia cases in which a mitochondrial component might 
be involved [71, 72].
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Many factors, generated by, or interconnected with COPD, could contribute to brain dysfunc-
tion and/or damage (Figure 1).
2.3. Clinical consequences of an affected cognition; measure methods
In order to diagnose MCI, besides the clinical and anamnestic examination, psychometric 
tests as well as neurochemistry and neuroimaging assessment are available.
Torres-Sánchez et al., in their meta-analysis listed more than 40 psychometric tests that 
were used [73]. The most used psychometric questionnaires are: the Mini Mental Status 
Examination (MMSE), the Clock Drawing test, the Trail Making test (TMT) A, the TMT B, 
Memory Impairment Screen (MIS); Montreal Cognitive Assessment test (MoCA) [74]. It is 
advisable to use a battery of tests, not a single one, to improve the result accuracy [75, 76].
Neuroimaging studies showed there are significantly lowered gray matter volumes in 
several brain regions as hippocamp [7], limbic and paralimbic structures [77], precuneus, 
bilateral calcarine, right superior temporal gyrus/middle temporal gyrus, bilateral fusiform, 
right inferior parietal lobule [78], cingulate and amygdala [8], dorsolateral prefrontal cor-
tex [77] etc., evidenced by different neuroimaging techniques based on magnetic resonance 
imaging (MRI). Performance accuracy has increased by introducing voxel-based morphom-
etry analysis also based on MRI. Using this technique, it was possible to show for the first 
Figure 1. Potential mechanisms contributing to brain dysfunction and/or damage in elderly subjects with COPD. HDAC: 
histone deacetylase, MMP9: matrix metalloproteinase 9, IL-6: interleukin 6, CRP: C-reactive protein, TNF-α: tumor 
necrosis factor, VCAM-1: vascular cell adhesion molecule-1.
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time gray matter volume alterations in stable COPD patients, even to those with subclinical 
cognitive impairment [79].
Passing over the slight contradictions or discrepancies between the results offered by these 
and other neuroimaging studies, what is common is heterogeneity and broad distribution of 
the lesions. Another important finding of neuroimaging studies is inferior parietal lobule and 
precuneus that are two regions altered also in COPD and Alzheimer disease.
Chronic airway involvement can be perceived as a strong aging factor leading to an early 
deterioration of cognition with a 10–15 years advanced age [2]. In a study on 301 stable mod-
erate-severe COPD patients conducted by Schure et al. showed that cognitive functioning 
(especially, psychomotor speed and executive control) present in approximately 30% of cases 
would be associated with greater disease severity and poorer physical functioning (as mea-
sured by the six-minute walk test, total steps per day and grip strength). And these results are 
more relevant as patients were “healthier” COPD, namely the patients without comorbidities 
known underlying inflammation (Charlson Index = 0.9–1.2) [80].
Due to the non-homogeneous distribution on the brain mapping, patients will experience var-
ious and multiple disorders, most of which are reflected by difficulties in naming, memory, 
visuospatial, executive function and mood decrements.
COPD-related dyspnoea is a strong driver to anxiety, panic or/and depression and reduced 
quality of life. But, development of a secondary cognitive impairment component may con-
tribute to increased behavioral disturbances; these may distress much more the family care-
givers which need to cope with behavioral changes.
In a study on 88 patients with COPD, Turan et al. showed a positive correlation between declin-
ing of cognitive function, assessed by MMSE questionnaire, and suboptimal inhalation adher-
ence, increasing hospitalizations and emergency visits [81]. In another study of 265 patients 
with COPD, adherence was measured using a tool incorporating sophisticated electronic 
devices to mark time and correctness of the technique; adherence over the study was 22.9% of 
what would be expected if all the doses had been taken correctly and on time, but more impor-
tant adherence was negatively influenced by impairment in cognitive function [82].
According to statistics, 41% of patients with stable COPD who undergo rehabilitation would 
suffer from any cognitive impairment. Inclusion and completion of a pulmonary rehabilitation 
program is however affected by the presence of cognitive impairment, the drop-out number 
being higher in those with cognitive impairment. However, the comparison of the different 
parameters (functional status, health status and psychological well-being) to the patients able 
to complete the program does not differ between cognitive impairment patients and those 
with no cognitive impairment, this being an argument that patients suffering from cognitive 
impairment can benefit from the programs rehabilitation [83]. Do not forget to investigate 
factors related to balance changes in patients with COPD. Although the risk of falls may seem 
less important than the consequences of COPD itself, falls are associated with increased mor-
tality, reduced independence, poorer quality of life and lower level of physical activity.
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Depression and anxiety are found in high proportions (30–70%) and identifying the coping styles 
in patients with COPD represent an important aspect of the individualized treatment of the 
patient, because the coping style can be both adaptive, implying the stress reduction and maladap-
tive, situation in which the maintenance and the amplification of the current symptomatology are 
present or can determine the appearance of some new symptomatic elements and behaviors [84].
The fact that cognitive impairment would occur at younger age [2], would cross a subclinical 
period [79] and would present at least 30% of cases [80], all of which signals us that cognitive 
impairment may be an early indicator of emerging risk of frailty and poor overall mental 
functioning among COPD patients.
Cognitive impairment has also been reported to worsen over time due to both the aggravation 
of COPD and the increase in burden represented by the progression and/or complications 
of comorbidities [85]. Chang et al. reported that the co-occurrence of COPD and cognitive 
impairment in a 3-year prospective study was associated with increased rate of disability, 
hospital admission and mortality [86].
3. Therapeutic implications; preventive strategies
How to deal with a COPD patient who might be suffering from cognitive impairment? Based 
on growing evidence in recent years, it is reasonable that cognitive assessment in subjects suf-
fering from chronic obstructive disease should enter the routine of diagnostic procedures to 
grade the overall impact of patients’ respiratory condition. Multiple areas of cognition being 
altered in varying degrees, may explain a poor awareness of the disease and may compromise 
the individual’s ability to manage his or her own care and adherence to treatment. The clini-
cian, who observes signs of forgetfulness, disorientation or balance trouble and/or even poor 
adherence to medical treatment, should prompt to conduct further assessments using screen-
ing tools (e.g. MMSE score).
Addressing comorbidities. The number of comorbidities increases with age progression. 
Specific attention must be focused on so-called cognitive comorbidities. They relate in partic-
ular to cardiovascular diseases, cerebrovascular diseases, diabetes mellitus and OSAS. These 
should be treated according to current guidelines.
Pulmonary rehabilitation. Balance training and fall prevention strategies are not included in 
international guidelines for PR, and very few programs include standardized balance assess-
ment. Although exercise can improve balance and decrease fall risk in older adults, interven-
tions that include exercise to challenge balance have greater effects on fall risk and balance. 
Physical exercise training involving balance, strength training, movement speed and coordi-
nation has improved balance and frailty markers in multiple randomized and nonrandom-
ized studies [87, 88]. Past cross-sectional research has provided support for the hypothesis 
that greater levels of aerobic fitness may be associated with a lessening of the normal age-
related declines in cognitive functioning [89, 90]. It is conceivable that improvements in 
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 cognitive functions such as executive function might help to improve self-management skills 
and potentially assist in sustaining the other substantial benefits of pulmonary rehabilitation.
Cognitive training. Given the increased prevalence of cognitive impairment in COPD and 
potentially devastating effects, a structured assessment of cognitive function should be imple-
mented as a routine component of the evaluation of COPD patients. Those identified with a 
screening tool as possibly having MCI should be referred for further assessment to a psychia-
trist. Identifying the coping styles in patients with COPD represents an important aspect of 
the individualized treatment of the patient. Interventions aiming at enhancing the problem- 
or emotion-focused coping may improve COPD prognosis [91].
Oxygen therapy: to whom? when? There is debate whether screening for cognitive impair-
ment should be routinely applied. From the point of view of the hypoxemia approach, the 
answer to this debate will have to consider the evidence: (1) one in four people with COPD 
have cognitive impairment and over time, cognitive decline will deepen (risking an evolution 
toward multi-infarct dementia or Alzheimer disease) [92–94]. (2) It is now recognized that not 
only continuous, but also intermittent hypoxia (efforts, daily activities and sleep) can by rep-
etition cause changes in brain neurochemistry and structure [7, 36]. (3) Cognitive impairment 
goes along with the severity of COPD, age and type/number of cognitive comorbidities. (4) 
Regular use of supplemental oxygen therapy has been shown to decrease the risk for cogni-
tive impairment in patients with COPD [37, 38, 95].
Therefore, even the detection of intermittent desaturation (effort, daily activity and sleep), 
will have to lead to establishing earlier oxygen supplementation in order to prevent irrevers-
ible brain damage.
4. Conclusions
At least 40% of COPD patients present irreversible neuronal damage or dysfunction that is 
separate from other comorbidities. That is why cognitive impairment has to be listed in the 
first line of extrathoracic manifestations. Not identifying cognitive impairment we miss the 
fact that this condition may be a precursor to develop dementia in about a third of cases, or 
even higher in the context of COPD associated with other comorbidities. Cognitive impair-
ment has been shown to increase the risk of hospitalization, disability and death. Hypoxemia 
is a serious problem that, even under the conditions of intermittent occurrence, should be 
sanctioned as early as possible by establishing LTOT. Besides oxygen therapy, the most effec-
tive therapeutic actions and strategies to these particular populations include: addressing 
comorbidities, pulmonary rehabilitation and cognitive training.
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